Skip to main content
SpringerLink
Log in

Options for Treatment of Primary Biliary Cirrhosis

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Primary biliary cirrhosis (PBC) is a chronic progressive cholestatic disease where there is progressive, granulomatous destruction of the middle-sized bile ducts. The disease affects mainly middle-aged women. The association with other autoimmune diseases and the widespread disturbance of the humoral and cellular immune systems has led to the inclusion of PBC as an autoimmune disease. However, there are several lines of evidence that suggest that both host and environmental factors are implicated in triggering the disease. Without a clear aetiology, it is difficult to find a logical approach to treatment.

Well constructed clinical trials are difficult to run because of the variable and long natural history of the disease; and suitable endpoints are difficult to define and validated surrogate endpoints have not been defined.

The only drug licensed for use is the bile acid, ursodeoxycholic acid. This drug is associated with significant biochemical improvement and improvement in the immunological disturbances (including a reduction in the titre of the diagnostic autoantibody, antimitochondrial antibody), but the effect on survival and histological progression is still controversial. There is little effect on symptoms. Nonetheless, its safety and lack of toxicity have meant that it has become the drug of choice and most studies now assess the effect of additional treatments. Many other agents have been studied. There is some evidence, from prospective, controlled studies, for a beneficial effect of azathioprine and ciclosporin (cyclosporine); evidence for a beneficial effect of corticosteroids and of mycophenolate is limited and there is little firm evidence for a beneficial effect of methotrexate, penicillamine, thalidomide or colchicine. Other treatments being evaluated include fibric acid derivatives (fibrates), NSAIDs and leukotriene antagonists. Liver transplantation remains the only option for end-stage disease but recurrence of disease may be found in the graft. Experimental therapies include antiretroviral therapy.

Symptomatic treatment is required for pruritus and the mainstays are the bile acid binding agents such as colestyramine. For those who are intolerant of the drug or where it is ineffective, rifampicin and naltrexone may be effective. There is no effective treatment for the associated lethargy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Laurin JM, Lindor KD. Primary biliary cirrhosis. Dig Dis 1994 Nov–Dec; 12(6): 331–50

    Article  PubMed  CAS  Google Scholar 

  2. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis 2003 Nov; 7(4): 779–94

    Article  PubMed  Google Scholar 

  3. Newton JL, Jones DE, Metcalf JV, et al. Presentation and mortality of primary biliary cirrhosis in older patients. Age Ageing 2000; 29: 305–9

    Article  PubMed  CAS  Google Scholar 

  4. Heathcote EJ. Management of primary biliary cirrhosis: the American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31(4): 1005–13

    Article  PubMed  CAS  Google Scholar 

  5. James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999; 30(2): 390–4

    Article  PubMed  CAS  Google Scholar 

  6. Verma A, Jazrawi RP, Ahmed HA, et al. Prescribing habits in primary biliary cirrhosis: a national survey. Eur J Gastroenterol Hepatol 1999; 11(8): 817–20

    Article  PubMed  CAS  Google Scholar 

  7. Paumgartner G, Beuers U. UDCA in cholestatic liver disease: mechanism of action and therapeutic use revisited. Hepatology 2002; 36: 525–31

    Article  PubMed  CAS  Google Scholar 

  8. Jazrawi RP, de Caestecker JS, Goggin PM, et al. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. Gastroenterology 1994; 106(1): 134–42

    PubMed  CAS  Google Scholar 

  9. Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997; 112(1): 226–35

    Article  PubMed  CAS  Google Scholar 

  10. Guldutuna S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993; 104(6): 1736–44

    PubMed  CAS  Google Scholar 

  11. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of UDCA therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354(9184): 1053–60

    Article  PubMed  CAS  Google Scholar 

  12. Neuberger J. URSO: panacea or placebo? Hepatology 2000; 31(4): 1027–8

    Article  PubMed  CAS  Google Scholar 

  13. Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999 Mar; 29(3): 644–7

    Article  PubMed  CAS  Google Scholar 

  14. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; (1): CD 000551

  15. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19(5): 1149–56

    Article  PubMed  CAS  Google Scholar 

  16. Lindor KD, Janes CH, Crippin JS, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21(2): 389–92

    PubMed  CAS  Google Scholar 

  17. Huet PM, Huet J, Deslauriers J. Portal hypertension in patients with primary biliary cirrhosis. In: Lindor KD, Heathcote EJ, Poupon R, editors. Primary biliary cirrhosis: from pathogenesis to treatment. London: Kluwer Academic Publishers, 1998: 87–91

    Chapter  Google Scholar 

  18. van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. J Hepatol 1996; 25(6): 887–94

    Article  PubMed  Google Scholar 

  19. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72(12): 1137–40

    Article  PubMed  CAS  Google Scholar 

  20. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113(3): 884–90

    Article  PubMed  CAS  Google Scholar 

  21. Roda E, Azzaroli F, Nigro G, et al. Improved liver tests and greater biliary enrichment with high dose UDCA in early stage primary biliary cirrhosis. Dig Liver Dis 2002; 34(7): 523–7

    Article  PubMed  CAS  Google Scholar 

  22. Pasha T, Heathcote J, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999; 29(1): 21–6

    Article  PubMed  CAS  Google Scholar 

  23. Yamazaki K, Suzuki K, Nakamura A, et al. Ursodeoxycholic acid inhibits eosinophil degranulation in patients with PBC. Hepatology 1999; 30: 71–8

    Article  PubMed  CAS  Google Scholar 

  24. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003; 38(1): 203–9

    Article  PubMed  CAS  Google Scholar 

  25. Corpechot C, Carrat F, Poupon R, et al. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002; 122(3): 652–8

    Article  PubMed  CAS  Google Scholar 

  26. Lanzini A, De Tavonatti MG, Panarotto B, et al. Intestinal absorption of the bile acid analogue 75Se-homocholic acidtaurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration. Gut 2003; 52(9): 1371–5

    Article  PubMed  CAS  Google Scholar 

  27. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89(5): 1084–91

    PubMed  CAS  Google Scholar 

  28. Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104(2): 519–26

    PubMed  CAS  Google Scholar 

  29. Jones EA, ten Kate FJW, ter Borg F, et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 1165–9

    PubMed  CAS  Google Scholar 

  30. Bonis PA, Kaplan M. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 1999; 117(2): 395–9

    Article  PubMed  CAS  Google Scholar 

  31. Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117(5): 1173–80

    Article  PubMed  CAS  Google Scholar 

  32. Hendrickse MT, Rigney E, Giaffer MH, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117(2): 400–7

    Article  PubMed  CAS  Google Scholar 

  33. Bach N, Bodian C, Bodenheimer H, et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 2003; 98(1): 187–93

    Article  PubMed  CAS  Google Scholar 

  34. Combes B, Emerson S, Flye NL. Primary biliary cirrhosis (PBC) Ursodiol (UDCA) plus Methotrexate or its Placebo study (PUMPS) [abstract]. Hepatology 2003; 38: 112

    Article  Google Scholar 

  35. Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117(4): 918–25

    Article  PubMed  CAS  Google Scholar 

  36. Angulo P, Jorgensen RA, Keach JC, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31(2): 318–23

    Article  PubMed  CAS  Google Scholar 

  37. Hempfling W, Grunhage F, Dilger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38(1): 196–202

    Article  PubMed  CAS  Google Scholar 

  38. Almasio PL, Floreani A, Chiaramonte M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 2000; 14(12): 1645–52

    Article  PubMed  CAS  Google Scholar 

  39. Lee YM, Kaplan MM. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate. Am J Gastroenterol 2003; 98(1): 205–8

    Article  PubMed  Google Scholar 

  40. Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991; 14(6): 990–3

    Article  PubMed  CAS  Google Scholar 

  41. Devlin J, O’Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 1999; 45 Suppl. 6: VI1–VI22

    Article  PubMed  Google Scholar 

  42. Neuberger J, Farrant M. Chapter 5. In: Williams R, Portmann B, Tan KC, editors. The practice of liver transplantation. Edinburgh: Churchill Livingstone, 1995

    Google Scholar 

  43. Poison RJ, Portmann B, Neuberger J, et al. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: clinical and histologic follow-up studies. Gastroenterology 1989; 97(3): 715–25

    Google Scholar 

  44. Balan V, Batts KP, Porayko MK, et al. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993; 18(6): 1392–8

    Article  PubMed  CAS  Google Scholar 

  45. Liermann Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001; 33(1): 22–7

    Article  PubMed  CAS  Google Scholar 

  46. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20(2): 137–40

    Article  PubMed  CAS  Google Scholar 

  47. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10(1): 1–7

    Article  PubMed  CAS  Google Scholar 

  48. Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation in patients with primary biliary cirrhosis: use of prognostic modeling. J Hepatol 1999; 30(2): 285–92

    Article  PubMed  CAS  Google Scholar 

  49. Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998; 28(1): 33–8

    Article  PubMed  CAS  Google Scholar 

  50. Kilmurry MR, Heathcote EJ, Cauch-Dudek K, et al. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? Hepatology 1996; 23(5): 1148–53

    PubMed  CAS  Google Scholar 

  51. UNOS. MELD/PELD calculator [online]. Available from URL: http://www.unos.org/resources/MeldPeldCalculator.asp [Accessed 2004 Jun 28]

  52. MacQuillan GC, Neuberger JM. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003; 7(4): 941–56

    Article  PubMed  Google Scholar 

  53. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in post-menopausal women. N Engl J Med 1993; 328: 460–4

    Article  PubMed  CAS  Google Scholar 

  54. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118(1): 145–51

    Article  PubMed  CAS  Google Scholar 

  55. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98(10): 2268–74

    PubMed  CAS  Google Scholar 

  56. Menon KV, Angulo P, Boe GM, et al. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 889–92

    Article  PubMed  CAS  Google Scholar 

  57. Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38(6): 573–8

    PubMed  CAS  Google Scholar 

  58. Miyaguchi S, Oda M, Saito H, et al. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. Hepatogastroenterology 1998; 45(23): 1457–61

    PubMed  CAS  Google Scholar 

  59. Leuschner M, Holtmeier J, Ackermann H, et al. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 2002; 14(12): 1369–76

    Article  PubMed  CAS  Google Scholar 

  60. Tan AC, Mulder CJ. Increased survival in advanced primary biliary cirrhosis patients with regular albumin infusions? Eur J Gastroenterol Hepatol 1999; 11(8): 927–30

    Article  PubMed  CAS  Google Scholar 

  61. Xu L, Shen Z, Guo L, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis. Proc Natl Acad Sci U S A 2003; 100: 8454–9

    Article  PubMed  CAS  Google Scholar 

  62. Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr Gastroenterol Rep 2002; 4: 45–51

    Article  PubMed  Google Scholar 

  63. Reddy A, Prince M, James OF, et al. Tamoxifen: a novel treatment for primary biliary cirrhosis? Liver Int 2004 Jun; 24(3): 194–7

    Article  PubMed  CAS  Google Scholar 

  64. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989; 97: 1268–74

    PubMed  CAS  Google Scholar 

  65. Poupon RE, Balkau B, Eschwege E, et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis: UDCA-PBC Study Group. N Engl J Med 1991; 324: 1548–54

    Article  PubMed  CAS  Google Scholar 

  66. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284–90

    PubMed  CAS  Google Scholar 

  67. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884–90

    Article  PubMed  CAS  Google Scholar 

  68. Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515–8

    Article  PubMed  CAS  Google Scholar 

  69. Poupon RE, Lindor KD, Pare’s A, et al. Combined analysis of the effects of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39: 12–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Liver Unit, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK

    Ye H. Oo &  James Neuberger

Authors
  1. Ye H. Oo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Neuberger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Neuberger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oo, Y.H., Neuberger, J. Options for Treatment of Primary Biliary Cirrhosis. Drugs 64, 2261–2271 (2004). https://doi.org/10.2165/00003495-200464200-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464200-00001

Keywords

Search

Navigation